Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what progress his Department has made on tackling the shortage of Pancreatic Enzyme Replacement Therapy drugs.

The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to boost production to mitigate the supply issue. Increased volumes of PERT are expected for 2025, and specialist importers have sourced unlicensed stock to assist in covering the gap in the market. In December, the Department issued further management advice to healthcare professionals. This directs clinicians to unlicensed imports when licensed stock is unavailable, and includes actions for integrated care boards to ensure local mitigation plans are implemented. The Department, in collaboration with NHS England, has created a public facing page to include the latest updates on PERT availability and easily accessible prescribing advice.